Biosimilars differentiated by innovative injection technology
FINOX-Biotech develops Biosimilars and combines them with specifically designed injection technologies. By this we positively differentiate our combination-products compared to the reference products.
With our biosimilars, we want to create value for patients, partners and our investors:
With our biosimilars, we want to create value for patients, partners and our investors:
- for patients - with safe, efficient, easy to administer and fairly priced treatment of the highest quality.
- for partners and investors - based on reciprocity, transparent business.
FINOX Device Technology develops injection technology for subcutaneous, intravenous or intramuscular administration of liquid medications for the Life Science Industry. Our injection technologies are differentiated by their simple and safe - thus compliance-promoting - handling.
Partnerships: FINOX is looking for interesting partnerships, both in the field of Biosimilars and for the marketing of our injection technologies - contact us!
FINOX was founded 2007 in Switzerland and has since been working on implementing the vision.
NEWS:
we are proud to announce that our DuoPen device technology platform has been awarded the international RedDot design award 2011!
Partnerships: FINOX is looking for interesting partnerships, both in the field of Biosimilars and for the marketing of our injection technologies - contact us!
FINOX was founded 2007 in Switzerland and has since been working on implementing the vision.
NEWS:
we are proud to announce that our DuoPen device technology platform has been awarded the international RedDot design award 2011!
